First-line camrelizumab plus chemotherapy followed by camrelizumab-apatinib maintenance for ES-SCLC: a single-arm phase II study
A combination of immunotherapy and chemotherapy shows promise for extensive-stage small cell lung cancer, a disease with historically limited treatment options.
This Phase 2 trial in Lung Cancer evaluated camrelizumab (anti-PD-1) plus chemotherapy induction followed by camrelizumab-apatinib maintenance for extensive-stage small cell lung cancer, an indication with limited treatment options and poor prognosis. The immune-antiangiogenic combination showed promising activity with biomarker-defined responder populations.
What the study was
- Study design
- Phase 2 clinical trial (non-randomized)
- Population
- Patients with extensive-stage SCLC
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Lung cancer (Amsterdam, Netherlands)
Why it surfaced
Phase 2 trial data for novel immune-antiangiogenic combination in ES-SCLC, a high-unmet-need malignancy; biomarker-guided responder identification adds precision oncology dimension.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.